Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
1. A method of treating a viral respiratory infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition, comprising a physiologically acceptable carrier and a fusion polypeptide, wherein the fusion polypeptide comprises a histidyl-tRNA synthetase (HRS) polypeptide fused to an Fc fragment, wherein the FIRS polypeptide consists of a sequence that has at least 95% identity along its length to SEQ ID NO: 6, comprises a WHEP domain, and lacks a functional aminoacylation domain.
2. The method of claim 1 , wherein the FIRS polypeptide consists of a sequence that has at least 98% identity along its length to SEQ ID NO: 6.
3. The method of claim 1 , wherein the N-terminal region of the HRS polypeptide polypeptide is truncated by 1, 2, or 3 amino acids.
4. The method of claim 1 , wherein the fusion polypeptide reduces cell migration of monocytes/macrophages in the subject in need thereof.
5. The method of claim 1 , comprising intravenously administering the pharmaceutical composition to the subject.
6. The method of any one of claims 1 - 5 , wherein the viral respiratory infection comprises a Severe Acute Respiratory Syndrome (SARS) infectious agent.